Author

E. Oliveira

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:flow cytometry· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

C. James· 2 shared E. Yara· 2 shared G. Caravagna· 2 shared G. Vlachogiannis· 2 shared J. Fernandez-Mateos· 2 shared S. Milite· 2 shared A. Acar· 1 shared A. Antoniou· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. James

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Therapeutic Targeting of TIM-4-L With Engineered T Cells for Acute Myeloid Leukemia

B. Cieniewicz, E. Oliveira, M. Saxton, D. Torabi, A. Bhatta, P. Kukutla, A. Arballo, Z. Yang, B. Yu, M. Fate, H. Ning, L. Corey, A. Maiti, D. Corey

This study identifies TIM-4-L as a novel target for T cell therapy in AML, showing engineered T cells effectively eliminate AML cells in vitro and in vivo.

Clinical Cancer Research · May 1, 2024Peer-reviewedCancer Biology

Epigenetic heritability of cell plasticity drives cancer drug resistance through one-to-many genotype to phenotype mapping

J. Fernandez-Mateos, S. Milite, E. Oliveira, G. Vlachogiannis, B. Chen, E. Yara, G. D. Cresswell, C. James, L. Patruno, G. Ascolani, A. Acar, T. Heide, I. Spiteri, A. Graudenzi, G. Caravagna, , A. Sottoriva

The paper shows how epigenetic heritability of cell plasticity contributes to cancer drug resistance through a one-to-many genotype-to-phenotype mapping.

bioRxiv · Nov 15, 2023 · PreprintCancer Biology

Negative selection may cause grossly altered but broadly stable karyotypes in metastatic colorectal cancer

W. Cross, S. Nowinski, G. Cresswell, M. Mossner, A. Banerjee, B. Lu, M. Williams, G. Vlachogiannis, L. Gay, A.-M. Baker, C. Kimberley, F. Whiting, H. Belnoue-Davis, P. Martinez, M. Traki, , Wat

This study analyzes longitudinal genomic data from colorectal cancer patients to show that negative selection stabilizes karyotypes during tumor progression and metastasis.

bioRxiv · Mar 26, 2020 · PreprintCancer Biology